CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of neurons to treat disease. With chemogenetics, target neuronal populations are modified using gene therapy to express a tunable ligand-gated ion channel. These ligand-gated ion channels are engineered to be highly responsive to a specific proprietary small molecule but are otherwise inactive. The interaction of the small molecule and engineered receptor allow for exquisite, dose-dependent control of the neurons to generate therapeutic effect.
CODA’s engineered receptors can modulate the activity of multiple neuronal types, with expression determined by adeno-associated virus (AAV) capsid and promoter selection. The result is the flexibility to treat many neurological disorders with varying underlying pathophysiology.
Founder (not involved anymore)